Advances in antidepressant therapy related to gut microbiota
10.12206/j.issn.2097-2024.202111034
- VernacularTitle:肠道菌群相关的抗抑郁治疗研究进展
- Author:
Qiannan WANG
1
;
Xinhui HUANG
1
;
Minxu YANG
1
;
Xingrui YANG
1
;
Kehan ZHU
1
;
Tingting ZHOU
2
,
3
Author Information
1. School of Pharmacy, Naval Medical University, Shanghai 200433, China.
2. School of Pharmacy, Naval Medical University, Shanghai 200433, China
3. Shanghai Key Laboratory for Pharmaceutical (Chinese Materia Medica) Metabolite Research, Shanghai 200433, China.
- Keywords:
depression;
gut microbiota;
microbiome-gut-brain axis
- From:
Journal of Pharmaceutical Practice and Service
2022;40(5):422-426
- CountryChina
- Language:Chinese
-
Abstract:
Objective This paper introduces the research progress on the pathogenesis of depression related to gut microbiota and provides the resources for the subsequent development of antidepressant drugs targeting gut microbiota. Methods 33 literatures on gut microbiota and depression in recent years were reviewed. The changes of gut microbiota diversity under depression were discussed from the perspectives of phylum, family and genus. The relationship between gut microbiota and the pathogenesis of depression was expounded at the molecular level, and the existing relevant studies were summarized. The feasibility of drug development targeting gut microbiota was explored. Results There is a relationship between gut microbiota disorder and depression. Existing biological agents such as probiotics can alleviate depression by adjusting the disorder of gut microbiota. Conclusion The imbalance of gut microbiota is closely related to the occurrence of depression, and the development of drugs targeting gut microbiota may become a new way to treat depression.
